Sign in
PRQR Stock Price, Chart, Stats & News
ProQR Therapeutics N.V.
Save
199.13M
Market cap
–
Current P/E
–
Forward P/E
PRQR chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 95.77% |
Operating margin | -272.97% |
Pretax margin | -264.75% |
Net margin | -264.86% |
Effective tax rate | -0.05% |
ROA | -37.35% |
ROE | -65.10% |
D/E | 0.28x |
Interest coverage ratio | – |
PRQR valuation
P/E | – |
P/S | 7.87x |
P/B | 2.48x |
P/CF | -2.33x |
P/FCF | -2.34x |
P/OCF | -2.33x |
PEG | -0.72x |
EV multiple | -5.04x |
About
ProQR Therapeutics N. V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes two primary drug candidates in advanced clinical stages: Sepofarsen is currently in a Phase II/III clinical trial, known as the ILLUMINATE trial, targeting Leber Congenital Amaurosis 10 (LCA10).
Similar securities
Based on sector and market capitalization
Report issue